THOMAS P. JACOBS, M.D.; ETHEL S. SIRIS, M.D.; JOHN P. BILEZIKIAN, M.D.; DELIA C. BAQUIRAN, M.S.N.; ELIZABETH SHANE, M.D.; ROBERT E. CANFIELD, M.D.
JACOBS TP, SIRIS ES, BILEZIKIAN JP, BAQUIRAN DC, SHANE E, CANFIELD RE. Hypercalcemia of Malignancy: Treatment with Intravenous Dichloromethylene Diphosphonate. Ann Intern Med. 1981;94:312-316. doi: 10.7326/0003-4819-94-3-312
Download citation file:
Published: Ann Intern Med. 1981;94(3):312-316.
Twelve patients with hypercalcemia associated with various malignancies were treated with intravenous dichloromethylene diphosphonate (Cl2MDP), a potent inhibitor of osteoclastic bone resorption, in doses of 2.5 mg/kg of body weight initially and 5.0 mg/kg thereafter for up to 7 days. Mean serum calcium concentration fell from 13.8 ± 0.6 mg/dL (SEM) before Cl2MDP to 9.8 ± 0.7 mg/dL (SEM) (p < 0.001) after 7 days. Urine calcium excretion fell from 775 ± 95 mg/g creatinine (SEM) to 272 ± 70 mg/g creatinine (SEM) (p < 0.005), and urine hydroxyproline excretion fell from 144 ± 28 mg/g creatinine (SEM) to 78 ± 18 mg/g creatinine (SEM) (p < 0.05) after treatment with Cl2MDP. The Cl2MDP was well tolerated, and adverse effects were limited to asymptomatic hypocalcemia in two patients. The ability of Cl2MDP to correct hypercalcemia and reduce urine calcium and hydroxyproline excretion in these patients is consistent with the hypothesis that increased bone resorption is primarily responsible for this complication of malignancy and suggests that Cl2MDP may be highly useful in managing this condition.
Learn more about subscription options.
Register Now for a free account.
Endocrine and Metabolism, Fluid and Electrolyte Disorders, Nephrology.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only